Publications

Winnike, JH, Pediaditakis, P, Wolak, J, McClelland, R, Watkins, PB, Macdonald, JM. Stable Isotope Resolved Metabolomics of Primary Human Hepatocytes Reveals a Stressed Phenotype. In Press, Metabolomics.

Robertson, DG, Watkins, PB and Reily, MD. Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci 120(supp; 1): S146-S170, 2011.   

Watkins PB, Desai M, Berkowitz S, Peters G, Horsmans Y, Larrey D, and Maddrey W.  Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH): Application of This Data Organization Tool to Phase III Clinical Trials of Rivaroxaban after Total Hip or Knee Replacement Surgery. Drug Safety 34 (3)243-252, 2011.

O’Connell, TM and Watkins, PB. The application of Metabolomics to predict drug-induced liver injury. Clin Pharmacol Ther 88 (3):394-9, 2010.

Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, Fontana RJ, Day CP, Chinnery PF.  Common POLG genetic variants increase the risk of sodium valproate induced liver injury and failure. Hepatology 52 (5):1791-1796, 2010.

Wetmore BA, Brees DJ, Singh R, Watkins PB, Andersen ME,  Loy J, and Thomas RS. Quantitative Analyses and Transcriptomic Profiling of Circulating mRNAs as Biomarkers of Rat Liver Injury. Hepatology 52 (6):2127-2139, 2010.

Winnike J H, LiZ, Wright FA, Macdonald JM, O’Connell TM, and Watkins PB.  Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-InducedHepatotoxicity in Humans.Clin Pharmacol Ther, Clin Pharmacol Ther, 88(1):45-51, 2010.

Fannin RD, Russo M, O’Connell TM, Gerrish k, Winnike JH, Macdonald J, JNewton J, Malik S,  Sieber SO, Parker J, Shah R, Zhou T, Watkins PB, Paules RS.  Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology51(1):227-36, 2010.

Winnike J H, Busby MG, Watkins PB, and O’Connell TM.  Effects of a prolonged standardized diet on normalizing the human metabolome. Am. J. Clin Nutr 90:1-6, 2009.

Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, Stylianou IM, Boorman GA, Russo MW, Sackler RS, Harris SC, Smith PC, Tennant R, Bogue M, Paigen K, Harris C, Contractor T, Wiltshire T, Rusyn I, Threadgill DW.   Mouse Model of the Human Population Reveals that Variants in CD44 Contribute to Acetaminophen-Induced Liver Injury in Humans.  Genome Research (9):1507-15. 2009.

Zhou T, Chou J, Watkins PB, Kaufmann WK.  Toxicogenomics: transcriptomic profiling for toxicology assessment. EXS, 99:325-66, 2009.

Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Rationale, Design and Conduct of the Drug Induced Liver Injury Network (DILIN) Prospective study. Drug Safety 32(1):55-68, 2009.

Hayashi, PH, Watkins, PB. Progress in our understanding of severe drug-induced liver injury. Liver Transplantation 15 (7):675-6, July 2009. 

Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury.  Hepatology 48(5):1680-9, 2008.

Chalasani N,  Fontana R, Bonkovsky H, Watkins PB, Davern T, Serrano J, Yang H, Rochon J.  Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States. Gastroenterology 135(6):1924-34, 2008.

Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, Mc Hutchinson JG.  The reliability of the RUCAM for assessing causality in drug-induced liver injury.  Hepatology 48(4)1175-83, 2008.

Chaluda PC, Vahdat HL, Sharp RR, Delosier TC, Watkins PB, Pusek SN, Blackshear PJ.  The Environmental Polymorphism Registry: a DNA resource to study genetic susceptibility loci.  Human Genet. 123(2):207-14, 2008.